<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//FR">
<HTML>
<HEAD>
 <LINK HRef="../CSS/ggrcm.css"   Rel="stylesheet" Type="text/css">
 <META name="description" content="M&eacute;dicaments &agrave; base de levomenthol">
 <META name="keywords" content="Centre Belge d'Information Pharmacoth&eacute;rapeutique; levomenthol">
 <TITLE>M&eacute;dicaments &agrave; base de L&eacute;vonorgestrel</TITLE>
</HEAD>

<BODY bgcolor="#FFFFFF" LeftMargin="0" RightMargin="0" TopMargin="0" BottomMargin="0" MarginWidth="0" MarginHeight="0">
  <A Name="TopOfPage"></A>

  <TABLE Width="100%" Border="0" CellPadding="0" CellSpacing="0">
   <TR> 
    <TD Width="10">&nbsp;</TD>
    <TD Width="30%"><A HRef="../HeaderTxt/LeCBIP.htm">Le C.B.I.P.</A></TD>
    <TD Width="30%"><A HRef="../HeaderTxt/NousContacter.htm">Nous contacter</A></TD>
    <TD Width="30%"><A HRef="../HeaderTxt/Liens.htm">Sites Int&eacute;ressantes</A></TD>
   </TR> 
   <TR> 
    <TD Width="10">&nbsp;</TD>
    <TD Width="30%" Class="footer">Bon &agrave; savoir</TD>
    <TD Width="30%"><A HRef="../Index.htm"><B>Le R&eacute;pertoire</B></A></TD>
    <TD Width="30%" Class="footer">Folia</TD>
   </TR> 
   <TR> 
    <TD ColSpan="4"><HR></TD>
   </TR> 
  </TABLE> 


  <TABLE Width="100%" Border="0" CellPadding="0" CellSpacing="10">
   <TR>
    <TD>
     <H1>M&eacute;dicaments &agrave; base de <FONT Color="red">L&eacute;vonorgestrel</FONT></H1>
     <TABLE Width="100%" Border="0" CellPadding="5" CellSpacing="10">
      <TR>
       <TD vAlign="top" Width="33%">
         <P><FONT CLASS="Text">6. Gyn&eacute;co-obst&eacute;trique<BR>6.2. Contraception<BR>6.2.1. Estroprogestatifs &agrave; usage contraceptif<BR>6.2.1.1. Estroprogestatifs oraux &agrave; usage contraceptif<BR></FONT><A Class="HYR_INMP"  HREF="../MPG/MPG_FBAA.htm">6.2.1.1.1. Pr&eacute;parations monophasiques de premi&egrave;re g&eacute;n&eacute;ration</A><BR>
         <A Class="MP_INMP"  HREF="../MPG/MPG_FBAA.htm#MP_01375">-Microgynon 50</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <P><FONT CLASS="Text">6. Gyn&eacute;co-obst&eacute;trique<BR>6.2. Contraception<BR>6.2.1. Estroprogestatifs &agrave; usage contraceptif<BR>6.2.1.1. Estroprogestatifs oraux &agrave; usage contraceptif<BR></FONT><A Class="HYR_INMP"  HREF="../MPG/MPG_FBAA.htm">6.2.1.1.2. Pr&eacute;parations monophasiques de deuxi&egrave;me g&eacute;n&eacute;ration</A><BR>
         <A Class="MP_INMP"  HREF="../MPG/MPG_FBAA.htm#MP_01369">-Lowette</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBAA.htm#MP_01374">-Microgynon 30</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBAA.htm#MP_01383">-Stediril-30</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBAA.htm#MP_02958">-Microgynon 20</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBAA.htm#MP_03370">-Nora-30</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBAA.htm#MP_04992">-Noranelle</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBAA.htm#MP_05734">-Lavinia</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBAA.htm#MP_05806">-Eleonor 20</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBAA.htm#MP_05807">-Eleonor 30</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <P><FONT CLASS="Text">6. Gyn&eacute;co-obst&eacute;trique<BR>6.2. Contraception<BR>6.2.1. Estroprogestatifs &agrave; usage contraceptif<BR>6.2.1.1. Estroprogestatifs oraux &agrave; usage contraceptif<BR></FONT><A Class="HYR_INMP"  HREF="../MPG/MPG_FBAA.htm">6.2.1.1.6. Pr&eacute;parations triphasiques</A><BR>
         <A Class="MP_INMP"  HREF="../MPG/MPG_FBAA.htm#MP_01389">-Trigynon</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBAA.htm#MP_01391">-Trinordiol</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBAA.htm#MP_05003">-Triaselle</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
       </TD>
       <TD vAlign="top" Width="33%">
         <P><FONT CLASS="Text">6. Gyn&eacute;co-obst&eacute;trique<BR>6.2. Contraception<BR>6.2.2. Progestatifs &agrave; usage contraceptif<BR>6.2.2.1. Progestatifs oraux &agrave; usage contraceptif (&ldquo;minipilule&rdquo;)<BR></FONT><A Class="HYR_INMP"  HREF="../MPG/MPG_FBBA.htm">6.2.2.1.2. L&eacute;vonorgestrel</A><BR>
         <A Class="MP_INMP"  HREF="../MPG/MPG_FBBA.htm#MP_01354">-Microlut</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <P><FONT CLASS="Text">6. Gyn&eacute;co-obst&eacute;trique<BR>6.2. Contraception<BR>6.2.3. Dispositifs intra-ut&eacute;rins (DIU)<BR>6.2.3.2. DIU &agrave; base de l&eacute;vonorgestrel (&ldquo;st&eacute;rilet hormonal&rdqu<BR></FONT><A Class="HYR_INMP"  HREF="../MPG/MPG_FBCB.htm">6.2.3.2.1. *</A><BR>
         <A Class="MP_INMP"  HREF="../MPG/MPG_FBCB.htm#MP_01363">-Mirena</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBCB.htm#MP_05759">-Jaydess</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBCB.htm#MP_05817">-Levosert</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <P><FONT CLASS="Text">6. Gyn&eacute;co-obst&eacute;trique<BR>6.2. Contraception<BR>6.2.4. Contraception d&rsquo;urgence<BR></FONT><A Class="HYR_INMP"  HREF="../MPG/MPG_FBD.htm">6.2.4.1. L&eacute;vonorgestrel</A><BR>
         <A Class="MP_INMP"  HREF="../MPG/MPG_FBD.htm#MP_01355">-Norlevo</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBD.htm#MP_02868">-Postinor</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <A Class="MP_INMP" HREF="../MPG/MPG_FBD.htm#MP_05870">-Levodonna</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
         <P><FONT CLASS="Text">6. Gyn&eacute;co-obst&eacute;trique<BR>6.3. M&eacute;nopause et substitution hormonale<BR>6.3.2. Associations estroprogestatives dans la m&eacute;nopause<BR>6.3.2.2. Estroprogestatifs par voie transdermique<BR></FONT><A Class="HYR_INMP"  HREF="../MPG/MPG_FCBB.htm">6.3.2.2.1. *</A><BR>
         <A Class="MP_INMP"  HREF="../MPG/MPG_FCBB.htm#MP_01400">-Feminova Plus</A> [<FONT class="footer">l&eacute;vonorgestrel</FONT>]<BR>
       </TD>
      </TR>
     </TABLE>
<P Class="datum">
 <A Href="#TopOfPage">
 <IMG SRC="../Images/TopOfPage.gif" Width="18" Height="10" Border="0" onmouseover="return escape('Haut de page')"></A>&nbsp;
</P>

    </TD>
   </TR>
  </TABLE>
 <TABLE Width="100%" Border="0" CellPadding="0" CellSpacing="10">
  <TR>
   <TD Align="center">
    <HR WIDTH="90%" SIZE="1" COLOR="#008000" NOSHADE>
    <SPAN Class="footer">
 Centre Belge d 'Information Pharmacoth&eacute;rapeutique (C.B.I.P. asbl) <BR>
 c/o Heymans Instituut, De Pintelaan 185, 9000 Gent<BR>
 </SPAN>
 <A HRef="" Target="_top" Class="footer_link"><font color="#0000FF"></font></A> -
 <A HRef="mailto:redaction@cbip.be" Class="footer_link"><font color="#0000FF">redaction@cbip.be</font></A>
 - <A HRef="../Headertxt/Avertissement.htm" target="_blank" class="footer_link"><FONT Color="#0000FF">Avertissement / Disclaimer</FONT></A>
   </TD>
  </TR>
 </TABLE>

<script language="JavaScript" type="text/javascript" SRC="../JS/wz_tooltip.js"></script>
</BODY>
</HTML>
